Chemotherapy Diabetes Pharmacy Management 
Pharmacy Times
JULY 16, 2025
The SERENA-6 trial used ctDNA monitoring to identify the development of a resistant ESR1 mutation in patients with hormone receptor–positive breast cancer receiving first-line aromatase inhibitor (AI) plus a CDK4/6 inhibitor.
Pharmacy Times
JUNE 27, 2025
Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. For this application, the FDA collaborated with the Australian Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JUNE 18, 2025
They are also more likely to have diabetes, pain, and disability than other groups. 11 STEPPING UP A LEVEL Pharmacy teams can also speak to and for their communities. For example, many Cambodian Americans who have lived in the US for years experience persistent treatment-resistant anxiety disorders and posttraumatic stress disorder.
Pharmacy Times
JUNE 9, 2025
doi:10.1056/NEJMoa1901963 Newsletter Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights. N Engl J Med. 2019;380:2020-2030. Subscribe Now!
Pharmacy Times
JUNE 11, 2025
Approximately 40% to 80% of patients with cancer who are assigned female at birth face possible infertility as a result of their cancer treatments, such as chemotherapy, radiation, and surgery. An additional 15% to 30% of cancer survivors who are assigned male at birth also face infertility as a result of chemotherapy.
Pharmacy Times
JUNE 17, 2025
Difficile COPD COVID-19 Cardiovascular Health Cervical Cancer Cholangiocarcinoma Cholesterol Chronic Kidney Disease Chronic Lymphocytic Leukemia Classical Hematology Colorectal Cancer Continuous Glucose Monitoring Cough and Cold Depression Dermatology Diabetes Digestive Health Dry Eye Disease Epilepsy Eye Care Flu Future of Pharmacy Gastrointestinal (..)
Pharmacy Times
JUNE 20, 2025
I think we’re getting to the point now where hematology and oncology both need services that can manage these types of side effects. Blood cancer patients are usually at higher risk due to prior chemotherapy, and maybe we don’t need the same kind of prophylactic medications for solid tumor patients. It’s really been a partnership.
Expert insights. Personalized for you.
26 
Let's personalize your content